PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer

NCT04544111 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

19

Enrollment

OTHER

Sponsor class

Conditions

Thyroid Cancer
Thyroid Cancer, Follicular
Papillary Thyroid Cancer
Follicular Thyroid Cancer
Hurthle Cell Tumor
Poorly Differentiated Thyroid Gland Carcinoma
Hurthle Cell Thyroid Neoplasia

Interventions

DRUG: Trametinib
DRUG: Dabrafenib
DRUG: PDR001

Sponsor

Memorial Sloan Kettering Cancer Center